BRIEF-FDA Approves First Adjuvant Therapy For Most Common Type Of Lung Cancer

AstraZeneca PLC: * FDA APPROVES FIRST ADJUVANT THERAPY FOR MOST COMMON TYPE OF LUNG CANCER

* FDA -APPROVED TAGRISSO AS FIRST ADJUVANT TREATMENT FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE A SPECIFIC TYPE OF GENETIC MUTATION * FDA - GRANTED APPROVAL OF TAGRISSO TO ASTRAZENECA Source text for Eikon: Further company coverage: